Uneven distribution of human papillomavirus 16 in cervical carcinoma in situ and squamous cell carcinoma in older females: A retrospective database study

Andersson,Sonia; Mints,Miriam; Gyllensten,Ulf; Lindell,Monica; Gustavsson,Inger; Lambe,Mats; Wilander,Erik

doi:10.3892/ol.2014.2347

Uneven distribution of human papillomavirus 16 in cervical carcinoma in situ and squamous cell carcinoma in older females: A retrospective database study

Authors:
- Sonia Andersson
- Miriam Mints
- Ulf Gyllensten
- Monica Lindell
- Inger Gustavsson
- Mats Lambe
- Erik Wilander
View Affiliations

Affiliations: Department of Women's and Children's Health, Division of Obstetrics and Gynecology, Karolinska Institute, Karolinska University Hospital Solna, Stockholm S‑171 76, Sweden, Department of Genetics and Pathology, Uppsala University, Uppsala S‑751 85, Sweden, Department of Clinical Pathology and Cytology, Uppsala University Hospital and Uppsala University, Uppsala S‑751 85, Sweden
Published online on: July 11, 2014 https://doi.org/10.3892/ol.2014.2347
Pages: 1528-1532

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Human papillomavirus (HPV) 16 is the dominant cofactor in cervical cancer development. The present report investigated the age‑specific prevalence of HPV16 in cervical carcinoma in situ (CIS) in females attending organised cervical cancer screening. A retrospective observational study was performed based on individual data from two databases. A total of 162 females aged between 20 and 65 years from Uppsala County, Sweden with CIS and an HPV test conducted between 2010 and 2011, preceding or concomitant to CIS diagnosis, were included. Females with cervical squamous cell carcinoma (SCC; n=35) were used for comparison. In total, 96% (n=156) of females with CIS were positive for high‑risk HPV; HPV16 was the most prevalent (44.5%), followed by HPV33/52/58 (19.5%), HPV31 (13.1%) and HPV18/45 (9.5%). HPV16 was most frequently detected in females with CIS aged between 20 and 29 years (73.6%) and least frequently detected in those aged between 50 and 65 years (33.3%), with a statistically significant age‑specific difference (P=0.001). Among the HPV16‑positive females, multiple infections were most frequent in the younger age groups. The prevalence of HPV16 in females with CIS decreased with age, whereas a high prevalence of HPV16 remained in females with SCC. These results may indicate that HPV16 has increased oncogenic potential in older females.

View Figures

View References

1	Walboomers JM, Jacobs MV, Manos MM, et al: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 189:12–19. 1999.
2	Khan MJ, Castle PE, Lorincz AT, et al: The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 97:1072–1079. 2005.
3	Li N, Franceschi S, Howell-Jones R, Snijders PJ and Clifford GM: Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer. 128:927–935. 2011.
4	Bouvard V, Baan R, Straif K, et al: A review of human carcinogens - Part B: biological agents. Lancet Oncol. 10:321–322. 2009.
5	de Sanjose S, Quint WG, Alemany L, et al: Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 11:1048–1056. 2010.
6	Smith JS, Lindsay L, Hoots B, et al: Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 121:621–632. 2007.
7	Ivansson EL, Gustavsson IM, Wilander E, Magnusson PK and Gyllensten UB: Temporal trends over 3 decades and intrafamilial clustering of HPV types in Swedish patients with cervical cancer in situ. Int J Cancer. 125:2930–2935. 2009.
8	The National Board of Health and Welfare. Cancer Incidence in Sweden 2008. The National Board of Health and Welfare; Stockholm, Sweden: 2009, (In Swedish). http://www.socialstyrelsen.se/publikationer2009/2009-12-1. Accessed December 1, 2009
9	Official Statistics of Sweden Statistics-Health and Medical Care. Cancer Incidence in Sweden 2009. The National Board of Health and Welfare Centre for Epidemiology; Stockholm, Sweden: 2010, (In Swedish). http://www.socialstyrelsen.se/publikationer2010/2010-12-17. Accessed December 17, 2010
10	Official Statistics of Sweden Statistics-Health and Medical Care. Causes of Death in Sweden 2009. The National Board of Health and Welfare Centre for Epidemiology; Stockholm, Sweden: 2011, (In Swedish). http://www.socialstyrelsen.se/publikationer2011/2011-3-22. Accessed March 22, 2011
11	Gyllensten U, Lindell M, Gustafsson I and Wilander E: HPV test shows low sensitivity of Pap screen in older women. Lancet Oncol. 11:509–510. 2010.
12	Gyllensten U, Gustavsson I, Lindell M and Wilander E: Primary high-risk HPV screening for cervical cancer in post-menopausal women. Gynecol Oncol. 125:343–345. 2012.
13	Gustavsson I, Juko-Pecirep I, Backlund I, Wilander E and Gyllensten U: Comparison between the Hybrid Capture 2 and the hpVIR real-time PCR for detection of human papillomavirus in women with ASCUS or low grade dysplasia. J Clin Virol. 45:85–89. 2009.
14	Gustavsson I, Lindell M, Wilander E, Strand A and Gyllensten U: Use of FTA card for dry collection, transportation and storage of cervical cell specimen to detect high-risk HPV. J Clin Virol. 46:112–116. 2009.
15	de Sanjosé S, Diaz M, Castellsagué X, et al: Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 7:453–459. 2007.
16	Bergstrom R, Sparen P and Adami HO: Trends in cancer of the cervix uteri in Sweden following cytological screening. Br J Cancer. 81:159–166. 1999.
17	Gunnell AS, Ylitalo N, Sandin S, et al: A longitudinal Swedish study on screening for squamous cell carcinoma and adenocarcinoma: evidence of effectiveness and overtreatment. Cancer Epidemiol Biomarkers Prev. 16:2641–2648. 2007.
18	Gustafsson L, Sparen P, Gustafsson M, et al: Low efficiency of cytologic screening for cancer in situ of the cervix in older women. Int J Cancer. 63:804–809. 1995.
19	Lindell M, Sanner K, Wikstrom I and Wilander E: Self-sampling of vaginal fluid and high-risk human papillomavirus testing in women aged 50 years or older not attending Papanicolaou smear screening. BJOG. 119:245–248. 2012.
20	Tanaka H, Karube A, Tanaka T and Nakagomi O: Much higher risk of premalignant and malignant cervical diseases in younger women positive for HPV16 than in older women positive for HPV16. Microbiol Immunol. 45:323–326. 2001.
21	Zehbe I, Wilander E, Delius H and Tommasino M: Human papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma than the prototype. Cancer Res. 58:829–833. 1998.
22	Richard C, Lanner C, Naryzhny SN, et al: The immortalizing and transforming ability of two common human papillomavirus 16 E6 variants with different prevalences in cervical cancer. Oncogene. 29:3435–3445. 2010.
23	Ronco G, Giorgi-Rossi P, Carozzi F, et al: Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 11:249–257. 2010.
24	Leinonen M, Nieminen P, Kotaniemi-Talonen L, et al: Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. J Natl Cancer Inst. 101:1612–1623. 2009.
25	Katki HA, Kinney WK, Fetterman B, et al: Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 12:663–672. 2011.